Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience

Faculty of Medicine

Assiut University

Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience

Research Authors
Sawsan M Moeen, Ola A Afifi, Ahmad F Thabet, Medhat A Saleh, Mohamed A Morad
Research Date
Research Department
Internal Medicine
Research Journal
The Egyptian Journal of Haematology
Research Member
Sawsan Mohamed Moeen Ibrahim
Research Publisher
Medknow
Research Vol
Volume 48 Issue 2
Research Website
https://scholar.google.com/scholar?oi=bibs&cluster=14321767449787589482&btnI=1&hl=en
Research Year
2023
Research_Pages
185-190
Research Abstract

Tyrosine kinase inhibitors (TKIs) have improved the prognosis of chronic myeloid leukemia (CML) by inhibiting the BCR-ABL kinase. There are concerns regarding the effect of TKI on hemostasis by inhibiting platelet aggregation; the possible reason for this is yet unclear.

Objectives

To study platelet aggregation response to different agonists [(adenosine diphosphate (ADP), collagen, and arachidonic acid (AA)] using platelet aggregometry in 75 CML-chronic phase (CML-CP) patients on TKI therapy, in complete hematologic response (CHR).